| INTRODUC TI ON
Ovarian cancer is a significant cause of mortality and morbidity in women. Despite progress in molecular biology, diagnostic imaging, multidisciplinary surgical intervention and oncology treatment, prognosis has remained poor. Women with ovarian cancer are often diagnosed at an advanced stage and hence the 5-year survival is <50%.
1,2 A fundamental step towards improving patient survival from ovarian cancer is to gain better knowledge of the mechanisms involved in the carcinogenesis process and thus focus on prevention and early detection.
Women with hereditary risk factors for ovarian cancer constitute 10-15% of all ovarian cancers; 3 and mutation carriers in the breast cancer susceptibility genes, BRCA 1−/2− , have defects in homologous recombination repair pathways. 4 The lifetime risk of ovarian cancer in these women is estimated to be 10-50%. 3 Further, the risk of developing ovarian cancer before the age of 50 in BRCA 2− carriers is 2-3%, compared with 10-21% in BRCA 1− carriers. 5 However, the individual risk varies substantially. Besides hereditary factors, epigenetics, tumor microenvironment and reproductive hormones may play a vital role in cancer initiation.
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Epidemiological studies have shown that high age at menopause and infertility increase ovarian cancer risk, whereas pregnancy, hysterectomy and salpingo-oophorectomy (SOE) reduce the risk. 9, 11 Furthermore, hormone replacement therapy raises the risk whereas combined oral contraceptives have shown a protective effect, 12, 13 especially in women with BRCA 1−/2− mutations. 14 Further, anti-estrogens and aromatase inhibitors exhibit anti-tumor effects in estrogen receptor-positive ovarian cancers.
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Various strategies to reduce the risk of ovarian cancer among carriers of risk genes have been used including screening, prophylactic SOE and the use of combined oral contraceptives.
Prophylactic SOE in women with BRCA mutations reduces the risk of ovarian, fallopian tube and primary peritoneal cancer by 71-95%. 16, 17 However, there are several negative consequences with prophylactic operations. These include premature menopause with climacteric symptoms, infertility, sexual dysfunction, increased morbidity and future mortality risk due to cardiovascular and bone effects.
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Mifepristone (MIFE) is the first synthetic selective progesterone receptor modulator (SPRM) developed which binds with five times higher affinity to progesterone on progesterone receptor (PGR). It has both antagonistic as well as weak agonistic properties, depending on the presence or absence of progesterone, which induces conformational change in the carboxy-terminal tail of PGR. [20] [21] [22] MIFE has been shown to have an anti-ovulatory effect as well as inducing a regulatory effect on endometrial development. 23 In vitro mifepristone treatment was previously shown to inhibit cell growth and induce apoptosis in anti-estrogen-resistant breast cancer cells.
25
However, there is very limited knowledge of SPRM effects on ovary in healthy fertile women. In vitro studies by Klijn 25 showed that mifepristone had a direct antagonistic effect on PGR-positive breast tumors. In mice, mifepristone has a preventive effect on BRCA-related mammary tumor development. 26 Previously, we have shown an
anti-proliferative effect of a low dose mifepristone in human breast tissues. 27 Furthermore, mifepristone has antagonist properties to the glucocorticoid receptor. 28, 29 Mesenchymal stem/stromal cells (MSC) are a key player in ovarian tumor microenvironment, which secretes cytokines such as interleukin-6 (IL6) in direct or paracrine fashion and induces tumorigenic potential in ovarian cancer cells. 30, 31 Mifepristone has been shown to modulate proliferation and differentiation capabilities in rat bone marrow MSC. 32 Hence, we hypothesize that mifepristone along with progesterone may have an anti-proliferative effect on BRCA 1−/2− ovarian MSC, thereby providing a tumor-preventive ovarian microenvironment.
| MATERIAL AND ME THODS

| Patient information
In this preclinical experimental study, women (n = 9) with a median age of 42 years, positively screened for BRCA 1−/2− mutation, were invited to participate in the study at their regular check-up visit at the gynecological department of Karolinska University Hospital, Stockholm. Fresh ovarian 4-mm punch biopsies were taken immediately after the prophylactic bilateral SOE. None of the women had a concomitant hysterectomy; however, two postmenopausal women were receiving ongoing adjuvant tamoxifen treatment due to breast cancer ( Table 1) . The histopathological report from all removed adnexa was benign. The ovarian punch biopsies were used to isolate and expand ovarian stem/stromal cells and study their effect upon mifepristone treatments.
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Key message
Combined in vitro treatment with mifepristone and progesterone has an anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA 1−/2− carriers by arresting cell-cycle progression at the G1-S phase.
| Ovarian mesenchymal stem/stromal cell isolation and characterization
Ovarian stromal cells from punch biopsies were isolated into single- 
| In vitro mifepristone treatment
To evaluate a dose response effect of mifepristone, sorted and ex- 
| Kinetic proliferation assays
Cell viability/proliferation assays were assessed on six expanded post-treatment was also calculated by performing linear regression analysis of the time kinetics curve for both increasing doses of mifepristone and combination treatment, using the formula
| In-cell enzyme-linked immunosorbent assay (ELISA) for proliferation markers
Markers actively involved in the cell cycle such as bromodeoxyur- were done using an ELISA plate reader between 580 and 600 nm wavelengths.
| Gene expression assays
After the above drug treatments, 20 ng pre-diluted complementary deoxyribose nucleic acid was used in triplicate in a real-time PCR (RT-PCR) with TaqMan® expression probes, analyzed using StepONE 
| Western blot
| Statistical analyses
Statistical analysis and graphic plots of in vitro treatments were constructed using GraphPad PRISM 7 (GraphPad Software Inc., San Deigo, CA, USA). Analysis of data from proliferation, viability and gene expression assays of in vitro treatments were checked for
Gaussian distribution with the Shapiro-Wilks test. The target genes were analyzed individually using one-way ANOVA (parametric) or the Kruskal-Wallis (non-parametric) test according to distribution and corrected for post-hoc corrections using the two-stage linear stepup procedure of Benjamini, Krieger and Yekutieli. Treatments showing a difference of P < 0.05 were considered statistically significant. 
| Ethics approval
| Mifepristone inhibits proliferation in a dosedependent manner
The in vitro effect of mifepristone was initially tested with two (Figure 2A .ii).
Viability 
| Combined progesterone plus mifepristone (PG+MIFE) treatment induces anti-proliferative effect albeit activating BCL2
We explored whether an optimal dose of mifepristone could have an Subsequently, PG+MIFE compared with HC+MIFE showed a downregulation with both tumor suppressors TP53 (FC: −12.8, P < 0.027; Figure 3B .iv) and PTEN (FC: 11.8; P < 0.044; Figure 3B .v), indicating a more favorable anti-proliferative effect of the combined progesterone plus mifepristone combination treatment.
| PG+MIFE treatment induces pro-apoptotic pathway and p21-mediated cell cycle arrest
We examined whether BCL2 overexpression with combined PG+MIFE treatment in BRCA 1−/2− MSC + activates the pro-apoptotic or anti-apoptotic pathway using two apoptotic cell markers, annexin-V and 7-AAD. −0.64 ± 1.2%, P < 0.05) and mifepristone only (9.99 ± 3.07% and 1.55 ± 2.16; Figure 4A .ii).
Further, we examined whether the pro-apoptotic effect mediated by BCL2 activates cellular apoptosis or cell-cycle arrest. Thus, we explored the presence of cleaved-Caspase 3 protein, a downstream target of apoptotic pathway by Western blot (Figure 4B .i).
However, we were not able to identify any band corresponding to cleaved fragments (32 and 23 kDa), whereas pro-caspase 3 protein were detected in equal amounts for all treatment groups, thus confirming the BCL2-mediated regulation of apoptosis. Correspondingly, we also investigated the key regulator of the G1-S cell-cycle checkpoint, p21 (cyclin-D kinase 2 inhibiting protein-CIP) for the above treatment groups. Moreover, we observed higher levels of p21 in PG+MIFE as well as only progesterone, whereas low levels were recorded for only mifepristone and only hydrocortisone, and were completely absent for the HC+MIFE combination. We also measured protein levels of CDK2, a direct target of p21 CIP which showed nonsignificant reduced levels, corresponding to higher levels of p21 with 
| D ISCUSS I ON
In the current study, we showed that a combined treatment with mifepristone and progesterone induces a potent anti-prolifera- 
